These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 3931929

  • 1. Mesna does not reduce cisplatin induced nephrotoxicity in the rat.
    Millar BC, Siddik ZH, Millar JL, Jinks S.
    Cancer Chemother Pharmacol; 1985; 15(3):307-9. PubMed ID: 3931929
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interaction between cisplatin and mesna in mice.
    Dorr RT, Lagel K.
    J Cancer Res Clin Oncol; 1989; 115(6):604-5. PubMed ID: 2514188
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
    Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ.
    Br J Cancer; 2004 Apr 19; 90(8):1654-9. PubMed ID: 15083199
    [Abstract] [Full Text] [Related]

  • 6. Nephrotoxicity and carcinogenic risk of cis-platin (CDDP) prevented by sodium 2-mercaptoethane-sulfonate (Mesna): experimental results.
    Kempf SR, Ivankovic S.
    Cancer Treat Rev; 1987 Dec 19; 14(3-4):365-72. PubMed ID: 3125972
    [No Abstract] [Full Text] [Related]

  • 7. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
    Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR.
    Cancer Chemother Pharmacol; 2010 Apr 19; 65(5):941-51. PubMed ID: 19714332
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
    Leeuwenkamp OR, Neijt JP, van der Vijgh WJ, Pinedo HM.
    Eur J Cancer; 1991 Apr 19; 27(10):1243-7. PubMed ID: 1835593
    [Abstract] [Full Text] [Related]

  • 10. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
    Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ.
    Biochem Pharmacol; 2004 Aug 01; 68(3):493-502. PubMed ID: 15242815
    [Abstract] [Full Text] [Related]

  • 11. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
    DeWoskin RS, Riviere JE.
    Toxicol Appl Pharmacol; 1992 Feb 01; 112(2):182-9. PubMed ID: 1311464
    [Abstract] [Full Text] [Related]

  • 12. Mesna inactivates platinum agents in vitro.
    Wolff JE, Egeler RM, Anderson R, Ujack E, Iceton S, Coppes MJ.
    Anticancer Res; 1998 Feb 01; 18(6A):4077-81. PubMed ID: 9891448
    [Abstract] [Full Text] [Related]

  • 13. Sodium 2-mercaptoethane sulfonate protection against cyclophosphamide-induced teratogenicity in rats.
    Slott VL, Hales BF.
    Toxicol Appl Pharmacol; 1986 Jan 01; 82(1):80-6. PubMed ID: 3080822
    [Abstract] [Full Text] [Related]

  • 14. Interaction between mesna and selected transition metals in vitro and in vivo.
    Shaw IC, Weeks MS.
    Arzneimittelforschung; 1986 Jun 01; 36(6):997-1000. PubMed ID: 3091043
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of rat hepatic microsomal lipid peroxidation by mesna via glutathione.
    Bast A, Haenen GR, Savenije-Chapel EM.
    Arzneimittelforschung; 1987 Sep 01; 37(9):1043-5. PubMed ID: 3124863
    [Abstract] [Full Text] [Related]

  • 16. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
    Kunze E, Köhnecke B, Engelhardt W, Steinröder H, Brock N, Pohl J.
    Urol Int; 1984 Sep 01; 39(2):61-7. PubMed ID: 6426112
    [Abstract] [Full Text] [Related]

  • 17. In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide--a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity.
    Pool BL, Bos RP, Niemeyer U, Theuws JL, Schmähl D.
    Toxicol Lett; 1988 Apr 01; 41(1):49-56. PubMed ID: 3128896
    [Abstract] [Full Text] [Related]

  • 18. [Autoradiographic studies on the protective effect of mesna in the urinary bladder mucosa of the rat during administration of cyclophosphamide (preliminary communication)].
    Kunze E, Köhnecke B, Engelhardt W, Brock N, Pohl J.
    Arzneimittelforschung; 1983 Apr 01; 33(6):853-4. PubMed ID: 6412725
    [Abstract] [Full Text] [Related]

  • 19. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
    Ormstad K, Ohno Y.
    Cancer Res; 1984 Sep 01; 44(9):3797-800. PubMed ID: 6430554
    [Abstract] [Full Text] [Related]

  • 20. Studies on the toxicity of cyclophosphamide in combination with mesna in vitro and in vivo.
    Millar BC, Millar JL, Clutterbuck R, Jinks S.
    Cancer Treat Rev; 1983 Sep 01; 10 Suppl A():63-71. PubMed ID: 6414698
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.